This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
prostate-cancer
Prostate Cancer
Second leading cancer death in men; driven by androgen receptor (AR) signaling; PTEN loss (~50%) and AR amplification underlie castration-resistant progression. Docetaxel, abiraterone, enzalutamide, olaparib (BRCA-mutant HRR deficient), and lutetium-177-PSMA are active in mCRPC.
Entry Metadata
| Field | Value |
|---|---|
| ID | prostate-cancer |
| Name | Prostate Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433. · PubMed 24881730
- Sartor O, de Bono J, Chi KN, et al. Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. · PubMed 34161051
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102. · PubMed 32343890